Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials

Post-hoc analysis (n=8416) found semaglutide liked to initial reductions in eGFR that plateaued, and marked reductions in urine albumin-to-creatinine ratio, suggesting no increase in risk of kidney adverse events with semaglutide vs. active comparators used across SUSTAIN 1–7.

Source:

The Lancet Diabetes & Endocrinology